{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:09:27Z","timestamp":1780103367682,"version":"3.54.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["MAIN457_FVKH002"],"award-info":[{"award-number":["MAIN457_FVKH002"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112569","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:14:08Z","timestamp":1640736848000},"page":"112569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Expression and activity of IL-17 receptor subunits in human cutaneous cells as targets for anti-IL-17 therapeutic antibodies"],"prefix":"10.1016","volume":"146","author":[{"given":"Johannes","family":"Wohlrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Gerloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.molmed.2016.01.001","article-title":"IL-17 in chronic inflammation: from discovery to targeting","volume":"22","author":"Beringer","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2021.112569_bib2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112569_bib3","article-title":"Role of IL-17 in atopy\u2013a systematic review","volume":"13","author":"Hofmann","year":"2021","journal-title":"Clin. Transl. Allergy"},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cytogfr.2010.10.002","article-title":"IL-17 family member cytokines: regulation and function in innate immunity","volume":"21","author":"Reynolds","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2021.112569_bib6","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2021.112569_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.coi.2011.07.006","article-title":"Recent advances in the IL-17 cytokine family","volume":"23","author":"Gaffen","year":"2011","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112569_bib8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni.1813","article-title":"Structural basis of receptor sharing by interleukin 17 cytokines","volume":"10","author":"Ely","year":"2009","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112569_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.biopha.2021.112569_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/intimm\/dxn106","article-title":"The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation","volume":"20","author":"Annunziato","year":"2008","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib11","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.112569_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni1449","article-title":"IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge","volume":"8","author":"Khader","year":"2007","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2021.112569_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","author":"Fowler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"19","key":"10.1016\/j.biopha.2021.112569_bib16","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112569_bib18","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2021.112569_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/jfmpc.jfmpc_689_19","article-title":"Update on psoriasis: a review","volume":"9","author":"Rajguru","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/13696998.2018.1431921","article-title":"Comorbidity and economic burden among moderate-to-severe psoriasis and\/or psoriatic arthritis patients in the US Department of Defense population","volume":"21","author":"Lee","year":"2018","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jamadermatol.2017.5417","article-title":"Association of psoriasis with comorbidity development in children with psoriasis","volume":"154","author":"Tollefson","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjd.17335","volume":"180","author":"Ellis","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jdv.15879","article-title":"Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis","volume":"34","author":"Erichsen","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cyto.2008.07.017","article-title":"An overview of IL-17 function and signaling","volume":"43","author":"Gaffen","year":"2008","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.biopha.2021.112569_bib29","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/jid.2011.222","article-title":"IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms","volume":"131","author":"Shi","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112569_bib30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jid.2019.01.006","article-title":"Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes","volume":"139","author":"Moos","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112569_bib31","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jid.2019.01.014","article-title":"IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis","volume":"139","author":"Ekman","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.biopha.2021.112569_bib32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/exd.13284","article-title":"Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes","volume":"26","author":"Cheuk","year":"2017","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/rheumatology\/kel159","article-title":"Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways","volume":"46","author":"Kim","year":"2007","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.112569_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2017.00001","article-title":"Upregulation of TH\/IL-17 pathway-related genes in human coronary endothelial cells stimulated with serum of patients with acute coronary syndromes","volume":"4","author":"Cimmino","year":"2017","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/xen.12291","article-title":"Human IL-6, IL-17, IL-1beta, and TNF-alpha differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells","volume":"24","author":"Gao","year":"2017","journal-title":"Xenotransplantation"},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/etm.2015.2939","article-title":"IL-17 promotes keratinocyte proliferation via the downregulation of C\/EBPalpha","volume":"11","author":"Ma","year":"2016","journal-title":"Exp. Ther. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112569_bib38","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02634257","article-title":"A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin","volume":"31","author":"Normand","year":"1995","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0305-4179(95)00085-2","article-title":"Human keratinocyte isolation and cell culture: a survey of current practices in the UK","volume":"22","author":"Daniels","year":"1996","journal-title":"Burns"},{"key":"10.1016\/j.biopha.2021.112569_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-62703-330-5_21","article-title":"Skin-derived mesenchymal stem cells: isolation, culture, and characterization","volume":"989","author":"Orciani","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"21","key":"10.1016\/j.biopha.2021.112569_bib42","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1007\/s00018-004-4288-4","article-title":"Isolation of human epidermal stem cells by adherence and the reconstruction of skin equivalents","volume":"61","author":"Kim","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.112569_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3349\/ymj.1996.37.3.186","article-title":"Isolation and pure culture of microvascular endothelial cells from the fetal skin","volume":"37","author":"Cha","year":"1996","journal-title":"Yonsei Med. J."},{"issue":"5","key":"10.1016\/j.biopha.2021.112569_bib44","first-page":"745","article-title":"Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis","volume":"71","author":"Kraling","year":"1994","journal-title":"Lab. Invest."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.112569_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0022-1759(84)90147-9","article-title":"Comparison of in vitro cell cytotoxic assays for tumor necrosis factor","volume":"68","author":"Flick","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2307\/3574477","article-title":"Effects of tritium-labeled pyrimidine nucleosides on epithelial cell proliferation in the mouse. I. Cytodynamic perturbations in normal circadian rhythms after a single injection of 3H-thymidine","volume":"68","author":"Olsson","year":"1976","journal-title":"Radiat. Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.112569_bib47","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2018.07.016","article-title":"Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?","volume":"107","author":"Singh","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2021.112569_bib48","first-page":"411","article-title":"Adverse drug reactions to biologics","volume":"8","author":"Scherer","year":"2010","journal-title":"J. Dtsch Dermatol. Ges."},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.112569_bib49","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1007\/s11739-011-0611-x","article-title":"Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction","volume":"7","author":"Vultaggio","year":"2012","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.biopha.2021.112569_bib50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000335614","article-title":"Etiology and pathogenesis of adverse drug reactions","volume":"97","author":"Hausmann","year":"2012","journal-title":"Chem. Immunol. Allergy"},{"issue":"4","key":"10.1016\/j.biopha.2021.112569_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mcna.2010.03.001","article-title":"The complex clinical picture of side effects to biologicals","volume":"94","author":"Hausmann","year":"2010","journal-title":"Med. Clin. N. Am."},{"issue":"8","key":"10.1016\/j.biopha.2021.112569_bib52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.biopha.2021.112569_bib53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Gutowska-Owsiak","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112569_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2133.2011.10302.x","article-title":"Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors","volume":"165","author":"Muhr","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.biopha.2021.112569_bib55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fimmu.2020.00220","article-title":"T-cell proapoptotic and antifibrotic activity against autologous skin fibroblasts in vitro is associated with IL-17A axis upregulation in systemic sclerosis","volume":"11","author":"Vettori","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2021.112569_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109741","article-title":"Interleukin-17A induces renal fibrosis through the ERK and Smad signaling pathways","volume":"123","author":"Weng","year":"2020","journal-title":"Biomed. Pharmacother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:48:07Z","timestamp":1779965287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221013561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":56,"alternative-id":["S0753332221013561"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112569","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression and activity of IL-17 receptor subunits in human cutaneous cells as targets for anti-IL-17 therapeutic antibodies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112569"}}